Cipla Q4 Review - Weak India Performance; Cut Estimates By 11-12%: Motilal Oswal
A technician inspects vaccine vials for defects at a pharmaceutical plant in Pune. (Photographer: Sanjit Das/Bloomberg)

Cipla Q4 Review - Weak India Performance; Cut Estimates By 11-12%: Motilal Oswal

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Motilal Oswal Report

Cipla Ltd. delivered a weaker-than-expected performance in Q4 FY21, weighed by moderate YoY growth in India domestic formulation/South Africa and YoY decline in active pharmaceutical ingredient sales for the quarter.

The company’s FY22 goals include:

  1. Ramping up the Covid-19 portfolio

  2. Outperforming in the generics franchise in India/South Africa

  3. Prioritising potential complex generics launches in the U.S.

  4. Scaling up the business in Europe, emerging markets

  5. Accelerating digital transformation across markets

We cut our earnings per share estimate by 12%/11% for FY22/FY23E, factoring in:

  1. Lower operating leverage

  2. Increased price erosion in the U.S. base business

  3. Inferior execution in the API segment

Click on the attachment to read the full report:

Motilal Oswal Cipla Q4FY21 Result Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.